Pneumococcal vaccination and risk of myocardial infarction

Lamontagne, François; Garant, Marie-Pierre; Carvalho, Jean-Christophe; Lanthier, Luc; Smieja, Marek; Pilon, Danielle
October 2008
CMAJ: Canadian Medical Association Journal;10/7/2008, Vol. 179 Issue 8, p773
Academic Journal
Background: Based on promising results from laboratory studies, we hypothesized that pneumococcal vaccination would protect patients from myocardial infarction. Methods: We conducted a hospital-based case-control study that included patients considered to be at risk of myocardial infarction. We used health databases to obtain hospital diagnoses and vaccination status. We compared patients who had been admitted for treatment of myocardial infarction with patients admitted to a surgical department in the same hospital for a reason other than myocardial infarction between 1997 and 2003. Results: We found a total of 43 209 patients who were at risk; of these, we matched 999 cases and 3996 controls according to age, sex and year of hospital admission. Cases were less likely than controls to have been vaccinated (adjusted odds ratio [OR] 0.53, 95% confidence interval [CI] 0.40-0.70). This putative protective role of the vaccine was not observed for patients who had received the vaccine up to 1 year before myocardial infarction (adjusted OR 0.85, 95% CI 0.54-1.33). In contrast, if vaccination had occurred 2 years or more before the hospital admission, the association was stronger (adjusted OR 0.33, 95% CI 0.20-0.46). Interpretation: Pneumococcal vaccination was associated with a decrease of more than 50% in the rate myocardial infarction 2 years after exposure. If confirmed, this association should generate interest in exploring the putative mechanisms and may offer another reason to promote pneumococcal vaccination.


Related Articles

  • Pneumococcal Vaccination and Risk of Acute Myocardial Infarction and Stroke in Men. Hung Fu Tseng; Slezak, Jeffrey M.; Quinn, Virginia P.; Sy, Lina S.; Van Den Eeden, Stephen K.; Jacobsen, Steven J. // JAMA: Journal of the American Medical Association;5/5/2010, Vol. 303 Issue 17, p1699 

    The article discusses a study which investigated the association between pneumococcal vaccination and risk of acute myocardial infarction (MI) and stroke among men. The researchers conducted a prospective cohort study of Kaiser Permanente Northern and Southern California health plans. Such...

  • Omega-3 Status and the Relationship between Plasma Asymmetric Dimethylarginine and Risk of Myocardial Infarction in Patients with Suspected Coronary Artery Disease. Borgeraas, Heidi; Strand, Elin; Pedersen, Eva Ringdal; Dierkes, Jutta; Ueland, Per Magne; Seifert, Reinhard; Wilberg, Eirik Rebnord; Bohov, Pavol; Berge, Rolf K.; Nilsen, Dennis W. T.; Nygård, Ottar // Cardiology Research & Practice;2012, p1 

    Background. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase. A previous rat study revealed an ADMA lowering effect following treatment with omega-3 polyunsaturated fatty acids (n-3 PUFAs). We sought to examine if an association between plasma ADMA and risk...

  • Vaccine price driver of PVC7 introduction costs in Gambia.  // PharmacoEconomics & Outcomes News;Mar2014, Vol. 697 Issue 1, p9 

    The article discusses research being done on the costs of vaccine delivery in Gambia following introduction of pentavalent and pneumococcal conjugate vaccine, conducted by E. Usuf et al, in the February 3, 2014 issue of the journal "Vaccine."

  • Space PCV7 doses at least eight weeks apart. Moskowitz, Andy // Infectious Diseases in Children;Jun2010, Vol. 23 Issue 6, p39 

    The article discusses research on the schedule of primary doses of PC7, which references a study by D. Goldblatt published in a 2010 issue of "Pediatric Infectious Disease Journal."

  • Association of the 894G>T polymorphism in the endothelial nitric oxide synthase gene with risk of acute myocardial infarction. Andrikopoulos, George K.; Grammatopoulos, Dimitris K.; Tzeis, Stylianos E.; Zervou, Sevasti I.; Richter, Dimitris J.; Zairis, Michalis N.; Gialafos, Elias J.; Sakellariou, Dimitris C.; Foussas, Stefanos G.; Manolis, Antonis S.; Stefanadis, Christodoulos I.; Toutouzas, Pavlos K.; Hillhouse, Edward W. // BMC Medical Genetics;2008, Vol. 9, Special section p1 

    Background: This study was designed to investigate the association of the 894G>T polymorphism in the eNOS gene with risk of acute myocardial infarction (AMI), extent of coronary artery disease (CAD) on coronary angiography, and in-hospital mortality after AMI. Methods: We studied 1602...

  • Coronary artery surgery for multivessel coronary artery disease reduces 10-year risk of myocardial infarction compared with medical treatment or percutaneous coronary intervention. Srinivas, Vankeepuram S.; Narasimhan, Seshasayee // Evidence Based Medicine;Apr2011, Vol. 16 Issue 2, p50 

    A review is presented of the article "Ten-Year Follow-Up Survival of the Medicine, Angioplasty, or Surgery Study (MASS II): A Randomized Controlled Clinical Trial of 3 Therapeutic Strategies for Multivessel Coronary Artery Disease" by W. Hueb, N. Lopes, B. J. Gersh et al., which appeared in a...

  • "Sizeable" societal savings from two-dose PCV13 schedule.  // PharmacoEconomics & Outcomes News;7/6/2013, Issue 683, p4 

    The article discusses research on the cost savings associated with removing the third, 6-month dose of the 13-valent pneumococcal conjugate vaccine (PCV13) primary dose series, referencing a study by C. Stoecker and colleagues published in the July 2013 issue of "Pediatrics."

  • Pneumococcal vaccine reduces US hospital admissions.  // Archives of Disease in Childhood;Oct2013, Vol. 98 Issue 10, p805 

    The article offers information on the study related to reduction of pneumococcal disease by the pneumococcal vaccine which resulted in decreased number of patients admissions in U.S. hospitals.

  • Dissertations and Features: Pneumococcal disease: More cases but fewer deaths.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article focuses on a research led by researchers from the Sahlgrenska Academy at the University of Gothenburg, Sweden, according to which the vaccine given to children to immunize against serious pneumococcal disease does not offer full protection.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics